<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922701</url>
  </required_header>
  <id_info>
    <org_study_id>IP-001-04</org_study_id>
    <nct_id>NCT00922701</nct_id>
  </id_info>
  <brief_title>L-Carnitine in Peritoneal Dialysis</brief_title>
  <official_title>Phase 2 Study of Dialysis Efficiency and Tolerability of Nocturnal Peritoneal Dialysis Solution Containing Glucose Plus L-carnitine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iperboreal Pharma Srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iperboreal Pharma Srl</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of glucose-sparing strategies able to provide an efficacious ultrafiltration
      profile represents one of the modern goals of peritoneal dialysis therapy. The study
      hypothesis is to evaluate the possibility to formulate peritoneal dialysis solutions
      containing L-carnitine as an osmotic agent to partially replace glucose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long Dwell Ultrafiltration</measure>
    <time_frame>day 5</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Peritoneal Dialysis Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-carnitine</intervention_name>
    <description>Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.</description>
    <arm_group_label>Peritoneal Dialysis Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥18 years

          -  Have a diagnosis of End Stage Renal Disease and have been on Continuous Ambulatory
             Peritoneal Dialysis for at least 3 months

          -  Be in a stable clinical condition during the four weeks immediately prior to Screening
             Period as demonstrated by medical history, physical examination and laboratory testing

          -  Have a blood hemoglobin concentration above 8,5 g/100ml (data will be verified with
             Investigators)

          -  Have not experienced peritonitis episodes in the last 3 months

          -  Be treated with 3 diurnal exchange bag solutions (1.5% or 2.5% glucose) and one
             nocturnal exchange bag solution (2.5% glucose)

          -  Have Kt/V urea measurement &gt; 1.7 per week in a previous test performed within 6 months
             that should be confirmed at Baseline Visit

          -  Have a minimum weekly creatinine clearance of 45 litres in a previous test performed
             within 6 months that should be confirmed at Baseline Visit

          -  Have a D/P Creatinine ratio at Peritoneal Equilibration Test between 0.50 and 0.81 in
             a previous test performed within 6 months that should be confirmed at Baseline Visit

          -  Have a D/P Glucose ratio at Peritoneal Equilibration Test between 0.26 and 0.49 in a
             previous test performed within 6 months that should be confirmed at Baseline Visit

          -  Be treated by the participating clinical Investigator for a period of at least three
             months

          -  Have understood and signed the Informed Consent Form.

        Exclusion Criteria:

          -  Have a history of drug or alcohol abuse in the six months prior to entering the
             protocol

          -  Be in treatment with androgens

          -  Have Diabetes Mellitus (as defined by the American Diabetes Society, objectively
             documented by a fasting plasma glucose and HbA1c determinations)

          -  Have clinically significant abnormal liver function test (SGOT, SGPT, and gamma-GT &gt; 2
             times the upper normal limit)

          -  Have acute infectious conditions (i.e.: pulmonary infection, acute hepatitis, high or
             low urinary tract infections, renal parenchymal infection, pericarditis, etc)

          -  Have a history of congestive heart failure and clinically significant arrhythmia

          -  Have an history of epilepsy or any central nervous system disease

          -  Have malignancy within the past 5 years, including lymphoproliferative disorders

          -  Have any medical condition that, in the judgment of the Investigator, would jeopardize
             the patient's safety following exposure to study drug, particularly if patient's life
             expectancy is less than 1 year

          -  Have a history of L-Carnitine therapy or use in the month prior to entering the
             protocol

          -  Have used any investigational drug in the 3 months prior to entering the protocol

          -  Pregnant, lactating, fertility age without protection against pregnancy by adequate
             contraceptive means
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Bonomini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>G. d'Annunzio University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arduino Arduini, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Iperboreal Pharma Srl</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Nephrology, University of &quot;G. d'Annunzio&quot;</name>
      <address>
        <city>Chieti</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2009</study_first_submitted>
  <study_first_submitted_qc>April 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <results_first_submitted>February 11, 2009</results_first_submitted>
  <results_first_submitted_qc>April 30, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2009</results_first_posted>
  <last_update_submitted>February 16, 2010</last_update_submitted>
  <last_update_submitted_qc>February 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Arduino Arduini, MD</name_title>
    <organization>Iperboreal Pharma Srl</organization>
  </responsible_party>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>L-carnitine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From June, 2004, to November, 2004. Medical Clinic</recruitment_details>
      <pre_assignment_details>One-week run-in</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peritoneal Dialysis Solution</title>
          <description>Patients were treated with a glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the long dwell. Peritoneal dialysis solution was instilled for 5 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peritoneal Dialysis Solution</title>
          <description>The enrolled patients were using for the long dwell (nocturnal) exchange a glucose-based (2.5% w/v) peritoneal dialysis solution.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.6" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ultrafiltration</title>
          <description>Ultrafiltration measured at the end of the long dwell (nocturnal) exchange</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1987" spread="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Long Dwell Ultrafiltration</title>
        <description>The amount of fluid recovered from the peritoneum at the end of the nocturnal exchange (long dwell) with a peritoneal dialysis solution.</description>
        <time_frame>day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peritoneal Dialysis Solution</title>
            <description>Patients were treated with a glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the long dwell. Peritoneal dialysis solution was instilled for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Long Dwell Ultrafiltration</title>
          <description>The amount of fluid recovered from the peritoneum at the end of the nocturnal exchange (long dwell) with a peritoneal dialysis solution.</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2167" spread="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Peritoneal Dialysis Solution</title>
          <description>Patients were treated with a glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the long dwell. Peritoneal dialysis solution was instilled for 5 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mario Bonomini, M.D.</name_or_title>
      <organization>University G. D'Annunzio</organization>
      <phone>+39 0871 540120</phone>
      <email>m.bonomini@nephro.unich.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

